Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
|Title:||Method for treatment of CNS-involved lysosomal storage diseases|
|Abstract:||A method is disclosed for the in vivo treatment of patients having a lysosomal storage disease with a significant central nervous system (CNS) involvement. Said method comprises administration to said patient a small but storage-inhibitory effective amount of an N-alkyl derivative of a 1,5-iminosugar in which said alkyl group contains from about 2 to about 8 carbon atoms and said 1,5-iminosugar is 1,5-dideoxy-1,5-imino-D-glucitol, or 1,5-dideoxy-1,5-imino-D-galactitol, or an O-acylated pro-drug of said 1,5-iminosugar. In an illustrative example, CNS storage of GM2 ganglioside is inhibited in Tay-Sachs mice by administration of 1,5-(butylimino)-1,5-dideoxy-D-glucitol.|
|Inventor(s):||Platt; Frances M. (Oxford, GB), Neises; Gabrielle R. (Chesterfield, MO), Dwek; Raymond A. (Oxford, GB), Butters; Terry D. (Oxford, GB)|
|Assignee:||Monsanto Company (St. Louis, MO)|
|Filing Date:||Jan 13, 1997|
|Claims:||1. A method for the treatment of a lysosomal storage disease having a significant central nervous system (CNS) involvement in a patient in need thereof comprising administering to said patient a storage-inhibitory effective amount of an N-alkyl derivative of a 1,5-iminosugar in which said alkyl group contains from about 2 to about 8 carbon atoms and said 1,5-iminosugar is 1,5dideoxy-1,5-imino-D-glucitol or 1,5-dideoxy-1,5-imino-D-galactitol, wherein from 1 to 4 of the free hydroxyl groups of said 1,5-iminosugar are optionally O-acylated. |
2. The method of claim 1 in which the 1,5-iminosugar is 1,5dideoxy-1,5-imino-D-glucitol.
3. The method of claim 1 in which the alkyl group is butyl.
4. The method of claim 1 in which the 1,5-iminosugar is 1,5dideoxy-1,5-imino-D-glucitol and the alkyl group is butyl.
5. The method of claim 4 in which the 1,5-iminosugar is O-acylated to form the tetrabutyrate.
6. The method of any of claims 1-5 in which the lysosomal storage disease is Tay-Sachs disease.
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.